Non-Viral Nanoparticle Delivery Systems in Stem Cell Reprogramming and Directed Differentiation

International Education, Beijing University of Chemical Technology, 102200 No.29, Nanjian Road, Nankou Town, China

^* Corresponding author: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

With the emergence of iPSCs, things in regenerative medicine took a turn. And it changed cell replacement therapy. But its clinical translation is very difficult. Viral have big danger of insertional mutagenesis. Uncontrolled programming factor dose is hard. This is a review of nonviral nanoparticles like lipids and solid lipid. To study the basics of theory and clinic. They’re used for these current bottlenecks. Pharmacokinetics and material science analysis indicates one key finding. Nanomaterials don’t use any genes. They do it with transitory cytoplasmic mRNA expression. And these can deliver the right amount, like with Oct4. They do it through things like changing the N/P ratio. These systems can be applied to certain pathologies as well. As well as such as Parkingson’s disease (PD), myocardial infarction (MI). Here, functionalized nanocarriers have a large pharmacodynamic. Longitudinal activation or sequential controlling of Wnt/Bc atcen. So it gets very homogeneous target cells. This paper reviews on how well it delivers without being a virus. And looks at real world, biomimetic nannocarriers. Lastly it talks about the risks and benefits of in vivo reprogramming towards tissue regeneration.